Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Amgen posts higher third-quarter sales, but trims full-year estimate

Published 11/02/2021, 04:18 PM
Updated 11/02/2021, 06:15 PM
© Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith
AMGN
-
JEF
-

By Deena Beasley

(Reuters) - Amgen Inc (NASDAQ:AMGN) on Tuesday said its quarterly revenue rose 4% as the impact of the COVID-19 pandemic began to ease, but said new prescriptions will be subdued through 2021 and prices for some drugs remain under pressure from lower-cost competition.

For the full year, the biotechnology company lowered the top end of its revenue forecast to $26.2 billion from a previous $26.6 billion. Wall Street analysts had forecast $26 billion, according to Refinitiv.

Amgen also slightly raised its outlook for 2021 adjusted earnings per share to between $16.50 and $17.10 from a previous range of $16.00 to $17.00.

Amgen shares closed up 2% at $214.26, but gave back most of those gain in extended trading and were down to $211 after hours.

The quarterly results were mostly in line with expectations, with investors next focusing on January, when Amgen is expected to hear from the U.S. Food and Drug Administration (FDA) on an application for asthma drug tezepelumab, Jefferies (NYSE:JEF) analyst Michael Yee said in a research note.

Adjusted earnings per share for the quarter, helped by share repurchases, were $4.69, beating the average analyst forecast of $4.27.

Full-year stock buy backs will come in near the high end of the company's estimated range of $3 billion to $5 billion, Chief Financial Officer Peter Griffith said on a conference call.

Amgen's net earnings fell 3% to $3.31 per share with a $400 million licensing-related expense from a collaboration with Japan's Kyowa Kirin Co Ltd.

Revenue for the quarter totaled $6.7 billion, up from $6.4 billion a year earlier, and in line with analyst expectations.

Amgen said sales volume for the quarter rose 8%, but net selling prices fell 7% as competition, including from cheaper generics and biosimilars, pushed down prices for its arthritis, migraine and infection-fighting drugs.

© Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith

Sales of arthritis drug Enbrel fell 3% from a year earlier to $1.29 billion. Sales of newer cancer drug Lumakras totaled $36 million for the quarter, ahead of analyst estimates of $28 million.

Chief Executive Bob Bradway said the impact of the COVID-19 pandemic - including a decline in face-to-face doctor visits - "has lingered longer than we thought it would at the beginning of the year."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.